Compare PLTK & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLTK | SNDX |
|---|---|---|
| Founded | 2010 | 2005 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 2014 |
| Metric | PLTK | SNDX |
|---|---|---|
| Price | $4.08 | $19.20 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $5.04 | ★ $38.69 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 11.46% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,755,400,000.00 | $172,352,000.00 |
| Revenue This Year | $2.60 | $107.19 |
| Revenue Next Year | $2.23 | $41.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.08 | ★ 627.84 |
| 52 Week Low | $2.64 | $12.10 |
| 52 Week High | $4.47 | $25.59 |
| Indicator | PLTK | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.00 | 35.86 |
| Support Level | $3.33 | $16.66 |
| Resistance Level | $4.26 | $22.40 |
| Average True Range (ATR) | 0.24 | 0.97 |
| MACD | 0.00 | -0.50 |
| Stochastic Oscillator | 72.39 | 7.34 |
Playtika Holding Corp is engaged in developing mobile games. Some of its games include Board Kings, House of Fun, Poker Heat, Slotomania, and Bingo Blitz. The company has built live game operations services and a proprietary technology platform to support its portfolio of games. It derives revenue from the sale of virtual items associated with online games. Geographically, the group has a business presence in the USA, EMEA, APAC, and Other regions of which key revenue is derived from the USA. The company offers both Mobile and Web-based platforms.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.